Evidence map›Paper›PMID 35218119›Full record

ArticleCancer science2022

Association between germline pathogenic variants and breast cancer risk in Japanese women: The HERPACC study.

Yumiko Kasugai, Tomohiro Kohmoto, Yukari Taniyama, Yuriko N Koyanagi, Yoshiaki Usui, Madoka Iwase, Isao Oze, Rui Yamaguchi, Hidemi Ito, Issei Imoto and 1 more

Abstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Yumiko KasugaiDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
Tomohiro KohmotoDivision of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Yukari TaniyamaDivision of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, Japan.
Yuriko N KoyanagiDivision of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID https://orcid.org/0000-0002-5675-3429
Yoshiaki UsuiDivision of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, Japan.
Madoka IwaseDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
Isao OzeDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID https://orcid.org/0000-0002-0762-1147
Rui YamaguchiDivision of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Hidemi ItoDivision of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID https://orcid.org/0000-0002-8023-4581
Issei ImotoAichi Cancer Center Research Institute, Nagoya, Japan.
Keitaro MatsuoDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID https://orcid.org/0000-0003-1761-6314

Funding

Aichi Cancer Center Joint Research Project on Priority AreasAMED JP15ck0106177AMED JP21ck0106553Cancer BioBank AichiGrant-in-Aid for the Third Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of JapanGrants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology of Japan 17015018Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology of Japan 221S0001Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology of Japan JP16H06277(CoBiA)Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology of Japan JP18H03045
6 · The paper itself

Abstract

Approximately 5%-10% of breast cancers are hereditary, caused by germline pathogenic variants (GPVs) in breast cancer predisposition genes. To date, most studies of the prevalence of GPVs and risk of breast cancer for each gene based on cases and noncancer controls have been conducted in Europe and the United States, and little information from Japanese populations is available. Furthermore, no studies considered confounding by established environmental factors and single-nucleotide polymorphisms (SNPs) identified in genome-wide association studies (GWAS) together in GPV evaluation. To evaluate the association between GPVs in nine established breast cancer predisposition genes including BRCA1/2 and breast cancer risk in Japanese women comprehensively, we conducted a case-control study within the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (629 cases and 1153 controls). The associations between GPVs and the risk of breast cancer were assessed by odds ratios (OR) and 95% confidence intervals (CI) using logistic regression models adjusted for potential confounders. A total of 25 GPVs were detected among all cases (4.0%: 95% CI: 2.6-5.9), whereas four individuals carried GPVs in all controls (0.4%). The OR for breast cancer by all GPVs and by GPVs in BRCA1/2 was 12.2 (4.4-34.0, p = 1.74E-06) and 16.0 (4.2-60.9, p = 5.03E-0.5), respectively. A potential confounding with GPVs was observed for the GWAS-identified SNPs, whereas not for established environmental risk factors. In conclusion, GPVs increase the risk of breast cancer in Japanese women regardless of environmental factors and GWAS-identified SNPs. Future studies investigating interactions with environment and SNPs are warranted.

Indexed as

Breast NeoplasmsCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGerm CellsHumansJapanLogistic ModelsPolymorphism, Single NucleotideRisk FactorsUnited Statesbreast cancercase-control studyenvironmental factorsgermline pathogenic variantssingle-nucleotide polymorphism

Identifiers

PMID35218119
PMCPMC8990868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.